285 related articles for article (PubMed ID: 18958345)
1. [Non-viral gene transfer results in therapeutic factor IX levels in haemophilia B mice].
Schüttrumpf J; Milanov P; Roth S; Seifried E; Tonn T
Hamostaseologie; 2008 Oct; 28 Suppl 1():S92-5. PubMed ID: 18958345
[TBL] [Abstract][Full Text] [Related]
2. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
[TBL] [Abstract][Full Text] [Related]
3. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
4. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
[TBL] [Abstract][Full Text] [Related]
5. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
Kim HS; Kim JC; Lee YK; Kim JS; Park YS
J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
[TBL] [Abstract][Full Text] [Related]
6. Clinical gene transfer studies for hemophilia B.
High KA
Semin Thromb Hemost; 2004 Apr; 30(2):257-67. PubMed ID: 15118937
[TBL] [Abstract][Full Text] [Related]
7. Factor IX: Insights from knock-out and genetically engineered mice.
Monahan PE
Thromb Haemost; 2008 Oct; 100(4):563-75. PubMed ID: 18841277
[TBL] [Abstract][Full Text] [Related]
8. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
[TBL] [Abstract][Full Text] [Related]
9. Transgene loss and changes in the promoter methylation status as determinants for expression duration in nonviral gene transfer for factor IX.
Schüttrumpf J; Milanov P; Abriss D; Roth S; Tonn T; Seifried E
Hum Gene Ther; 2011 Jan; 22(1):101-6. PubMed ID: 20677911
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.
Schneider H; Adebakin S; Themis M; Cook T; Douar AM; Pavirani A; Coutelle C
J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068
[TBL] [Abstract][Full Text] [Related]
11. Factor IX gene therapy for hemophilia.
Fewell JG
Methods Mol Biol; 2008; 423():375-82. PubMed ID: 18370215
[TBL] [Abstract][Full Text] [Related]
12. Persistent expression of canine factor IX in hemophilia B canines.
Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
[TBL] [Abstract][Full Text] [Related]
13. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells.
Wen J; Vargas AG; Ofosu FA; Hortelano G
J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997
[TBL] [Abstract][Full Text] [Related]
14. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
[TBL] [Abstract][Full Text] [Related]
15. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
Hasbrouck NC; High KA
Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
[TBL] [Abstract][Full Text] [Related]
16. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
[TBL] [Abstract][Full Text] [Related]
17. Towards gene therapy for hemophilia B.
Anson DS; Hock RA; Austen D; Smith KJ; Brownlee GG; Verma IM; Miller AD
Mol Biol Med; 1987 Feb; 4(1):11-20. PubMed ID: 3475525
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B.
Kao CY; Lin CN; Yang YL; Hamaguchi N; Yang SJ; Shen MC; Kao JT; Lin SW
Thromb Haemost; 2011 Apr; 105(4):616-26. PubMed ID: 21301787
[TBL] [Abstract][Full Text] [Related]
19. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.
Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE
Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for haemophilia "A" and "B": efficacy, safety and immune consequences.
Chuah MK; Vandendriessche T
Bull Mem Acad R Med Belg; 2007; 162(5-6):357-61. PubMed ID: 18405006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
